Itamar Medical Ltd.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Itamar Medical Ltd., operating as ZOLL Itamar, a division of ZOLL Medical Corporation following its 2021 acquisition for approximately $538 million, develops, manufactures and commercializes non-invasive medical devices and digital health solutions focused on sleep apnea diagnosis and management integrated into cardiac care pathways; core products include the FDA-cleared WatchPAT series (WatchPAT 300, WatchPAT ONE) for home sleep apnea testing (HSAT) utilizing peripheral arterial tonometry (PAT) technology to measure seven channels encompassing PAT signal, heart rate, oximetry, actigraphy, body position, snoring and chest motion with automated scoring for AHI, central sleep apnea, RDI, ODI and atrial fibrillation detection; associated services feature CloudPAT for HIPAA-compliant data transfer and remote interpretation, SleePATh for patient compliance monitoring and CPAP tracking, WatchPAT Direct for direct-to-consumer mail-order testing, and Total Sleep Solutions (TSS) encompassing screening, prior authorization, shipping, patient education, billing and reimbursement support. Founded in 1997 and headquartered in Caesarea, Israel, with U.S. operations in Atlanta, Georgia, and additional presence in Japan, Europe, Russia and India via subsidiaries including Itamar Medical Inc. and I.M.E. 2016 B.V., the company targets physicians in sleep medicine, cardiology and primary care serving undiagnosed sleep apnea patients, particularly those with cardiovascular comorbidities. ZOLL Itamar continues seamless operations post-acquisition under division president Gilad Glick with no material changes to its Israeli R&D, production and digital health centers, while leveraging ZOLL's global infrastructure to expand WatchPAT adoption and enhance collaborations between cardiology and sleep medicine sectors.
Itamar Medical Ltd. Sponsored ADR (ITMR) Reports Q3 Loss, Lags Revenue Estimates
Analysts Estimate Itamar Medical Ltd. Sponsored ADR (ITMR) to Report a Decline in Earnings: What to Look Out for
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Itamar Medical Ltd. with ZOLL Medical Corporation
ITMR Stock: The $538M Reason Why Itamar Medical Is Soaring 45% on Monday
Why Itamar Medical Stock Is Skyrocketing Today
ITMR Stock: Why It Significantly Increased Today
Itamar Medical Goes Private In $538M Deal: All You Need To Know
ZOLL Medical Corporation Signs Definitive Agreement to Acquire Itamar Medical
Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors
Itamar Medical Ltd.'s (ITMR) CEO Gilad Glick on Q2 2021 Results - Earnings Call Transcript
Itamar Medical Ltd. Sponsored ADR (ITMR) Reports Q2 Loss, Tops Revenue Estimates
Itamar Medical: Q2 Earnings Insights
Itamar Medical Reports Second Quarter 2021 Financial Results
Earnings Preview: Itamar Medical Ltd. Sponsored ADR (ITMR) Q2 Earnings Expected to Decline
Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021
Itamar Medical to Present at the Ladenburg Thalmann Annual Healthcare Conference on Wednesday, July 14, 2021
Itamar Medical Launches Enhancements to WatchPAT™ Product Line at SLEEP 2021
Itamar Medical Appoints Brad Fluegel to its Board of Directors
Itamar Medical Ltd. Sponsored ADR (ITMR) Moves 6.5% Higher: Will This Strength Last?
Itamar Medical Ltd. (ITMR) CEO Gilad Glick on Q1 2021 Results - Earnings Call Transcript